Hung Trinh: Pluripotent Stem-Cell-Derived Therapies in Clinical Trial
Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a recent article by Agnete Kirkeby et al, on LinkedIn, adding:
“Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
Since the first derivation of human pluripotent stem cells (hPSCs) 27 years ago, technologies to control their differentiation and manufacturing have advanced immensely, enabling increasing numbers of clinical trials with hPSC-derived products.
Here, we review the landscape of interventional hPSC trials worldwide, highlighting available data on clinical safety and efficacy. As of December 2024, we identify 115 clinical trials with regulatory approval, testing 83 hPSC products.
The majority of trials are targeting eye, central nervous system, and cancer. To date, more than 1,200 patients have been dosed with hPSC products, accumulating to >1011 clinically administered cells, so far showing no generalizable safety concerns.”
Title: Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
Authors: Agnete Kirkeby, Heather Main, Melissa Carpenter
Read the Full Article on Cell Stem Cell
More posts featuring Hung Trinh.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023